文献速递生殖医学

在多个完整IVF治疗周期中预测累积活产模型的的外部验证

External validation of models for predicting cumulative live birth over multiple complete cycles of IVF treatment.
PubMed 文献 · Hum Reprod · 2023-01-01

基于英国2010年1月至2016年12月91 035名接受IVF的女性数据,对McLernon模型进行外部验证,并收集2017年冻胚移植数据。更新后的治疗前模型区分度合理(c统计量0.67,95%CI 0.66-0.68),治疗后模型区分度良好(c统计量0.75,95%CI 0.74-0.76)。更新后的OPIS工具可帮助临床医生告知夫妇多个完整IVF周期的个体化活产机会。

要点

  • 更新后的治疗前模型c统计量0.67(95%CI 0.66-0.68),区分度合理。
  • 逻辑重校准后治疗后模型c统计量0.75(95%CI 0.74-0.76),区分度良好。
  • 更新后的OPIS工具可辅助告知夫妇多个完整IVF周期的个体化活产机会。

核心结论

  • 更新后的模型能更准确地估计多个完整IVF周期累积活产的个体化机会。

研究设计与样本

  • 基于人群的队列研究,纳入英国2010年1月至2016年12月期间91 035名接受IVF的女性,共144 734个完整周期,并收集2017年1月1日至2017年12月31日相关冻胚移植数据,数据来自人类受精与胚胎学管理局(HFEA)。

主要发现

  • 验证队列的年龄分布与开发队列相似,但验证队列中每名女性所有完整IVF周期的活产率更高。
  • 治疗前模型经系数修订后区分度合理(c统计量0.67,95%CI 0.66-0.68)。
  • 治疗后模型经逻辑重校准后区分度良好(c统计量0.75,95%CI 0.74-0.76)。
  • 更新后的治疗前模型示例:32岁女性,2年原发性不孕,第一个完整ICSI周期活产机会42%,三个完整周期77%。
  • 更新后的治疗后模型示例:30岁女性,2年原发性男性因素不孕,第一周期获卵15枚,移植1枚新鲜囊胚并冷冻剩余胚胎,第一个完整ICSI周期活产机会46%,三个完整周期81%。

临床怎么用

  • 更新后的OPIS工具可供临床医生使用,通过告知夫妇多个完整IVF周期的个体化活产机会来帮助调整其预期。

局限性

  • 原始模型中的两个预测因子(不孕持续时间和既往妊娠)在近期HFEA数据集中不可用,使用开发模型的较老队列数据进行填补。
  • HFEA数据集不包含其他一些可能重要的预测因子,如女性BMI、种族、民族、吸烟和酒精摄入,以及卵巢储备指标如窦卵泡计数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can two prediction models developed using data from 1999 to 2009 accurately predict the cumulative probability of live birth per woman over multiple complete cycles of IVF in an updated UK cohort? SUMMARY ANSWER: After being updated, the models were able to estimate individualized chances of cumulative live birth over multiple complete cycles of IVF with greater accuracy. WHAT IS KNOWN ALREADY: The McLernon models were the first to predict cumulative live birth over multiple complete cycles of IVF. They were converted into an online calculator called OPIS (Outcome Prediction In Subfertility) which has 3000 users per month on average. A previous study externally validated the McLernon models using a Dutch prospective cohort containing data from 2011 to 2014. With changes in IVF practice over time, it is important that the McLernon models are externally validated on a more recent cohort of patients to ensure that predictions remain accurate. STUDY DESIGN, SIZE, DURATION: A population-based cohort of 91 035 women undergoing IVF in the UK between January 2010 and December 2016 was used for external validation. Data on frozen embryo transfers associated with these complete IVF cycles conducted from 1 January 2017 to 31 December 2017 were also collected. PARTICIPANTS/MATERIALS, SETTING, METHODS: Data on IVF treatments were obtained from the Human Fertilisation and Embryology Authority (HFEA). The predictive performances of the McLernon models were evaluated in terms of discrimination and calibration. Discrimination was assessed using the c-statistic and calibration was assessed using calibration-in-the-large, calibration slope, and calibration plots. Where any model demonstrated poor calibration in the validation cohort, the models were updated using intercept recalibration, logistic recalibration, or model revision to improve model performance. MAIN RESULTS AND THE ROLE OF CHANCE: Following exclusions, 91 035 women who underwent 144 734 complete cycles were included. The validation cohort had a similar distribution age profile to women in the development cohort. Live birth rates over all complete cycles of IVF per woman were higher in the validation cohort. After calibration assessment, both models required updating. The coefficients of the pre-treatment model were revised, and the updated model showed reasonable discrimination (c-statistic: 0.67, 95% CI: 0.66 to 0.68). After logistic recalibration, the post-treatment model showed good discrimination (c-statistic: 0.75, 95% CI: 0.74 to 0.76). As an example, in the updated pre-treatment model, a 32-year-old woman with 2 years of primary infertility has a 42% chance of having a live birth in the first complete ICSI cycle and a 77% chance over three complete cycles. In a couple with 2 years of primary male factor infertility where a 30-year-old woman has 15 oocytes collected in the first cycle, a single fresh blastocyst embryo transferred in the first cycle and spare embryos cryopreserved, the estimated chance of live birth provided by the post-treatment model is 46% in the first complete ICSI cycle and 81% over three complete cycles. LIMITATIONS, REASONS FOR CAUTION: Two predictors from the original models, duration of infertility and previous pregnancy, which were not available in the recent HFEA dataset, were imputed using data from the older cohort used to develop the models. The HFEA dataset does not contain some other potentially important predictors, e.g. BMI, ethnicity, race, smoking and alcohol intake in women, as well as measures of ovarian reserve such as antral follicle count. WIDER IMPLICATIONS OF THE FINDINGS: Both updated models show improved predictive ability and provide estimates which are more reflective of current practice and patient case mix. The updated OPIS tool can be used by clinicians to help shape couples' expectations by informing them of their individualized chances of live birth over a sequence of multiple complete cycles of IVF. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by an Elphinstone scholarship scheme at the University of Aberdeen and Aberdeen Fertility Centre, University of Aberdeen. S.B. has a commitment of research funding from Merck. D.J.M. and M.B.R. declare support for the present manuscript from Elphinstone scholarship scheme at the University of Aberdeen and Assisted Reproduction Unit at Aberdeen Fertility Centre, University of Aberdeen. D.J.M. declares grants received by University of Aberdeen from NHS Grampian, The Meikle Foundation, and Chief Scientist Office in the past 3 years. D.J.M. declares receiving an honorarium for lectures from Merck. D.J.M. is Associate Editor of Human Reproduction Open and Statistical Advisor for Reproductive BioMed Online. S.B. declares royalties from Cambridge University Press for a book. S.B. declares receiving an honorarium for lectures from Merck, Organon, Ferring, Obstetric and Gynaecological Society of Singapore, and Taiwanese Society for Reproductive Medicine. S.B. has received support from Merck, ESHRE, and Ferring for attending meetings as speaker and is on the METAFOR and CAPRE Trials Data Monitoring Committee. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Ratna MB, Bhattacharya S, McLernon DJ, et al. External validation of models for predicting cumulative live birth over multiple complete cycles of IVF treatment. Hum Reprod. 2023. PMID: 37632223. doi:10.1093/humrep/dead165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。